Výsledky vyhledávání - "Thomas S. Stanton"

INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Autor: Aaron R. Hansen, Michael Chisamore, Helen Zhou, Ezra E.W. Cohen, Marc S. Ballas, Kelly Bell, Danny Rischin, Hisham Mehanna, Carlos Baccan, Rosalida Leone, Sapna Yadavilli, Thomas S. Stanton, Catherine E. Ellis, Axel Hoos, Min Hee Hong, David C. Turner, Helen Chen

Publikováno v: Journal of Clinical Oncology. 38:TPS6591-TPS6591

TPS6591 Background: Pembrolizumab as part of first-line treatment for patients (pts) with R/M HNSCC has improved survival. However, in order to further improve outcomes in this population investigation of rational combinations targeting different mec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::373a1b1ab6c08bc3a7d8fd96f4de8efd
https://doi.org/10.1200/jco.2020.38.15_suppl.tps6591

Zobrazit plný text záznamu

Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2

Publikováno v: Journal of Clinical Oncology. 37:5031-5031

5031 Background: The phase 2 TRITON2 study (NCT02952534) is evaluating the PARP inhibitor rucaparib in patients with mCRPC who have a deleterious germline or somatic alteration in BRCA ( BRCA1 or BRCA2) or 1 of 13 other DNA damage repair genes. Here

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ccdb6957972050717618f7fe70f08e5
https://doi.org/10.1200/jco.2019.37.15_suppl.5031

Zobrazit plný text záznamu

TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

Publikováno v: Journal of Clinical Oncology. 36:TPS388-TPS388

TPS388 Background: Up to 25% of patients with advanced prostate cancer, including mCRPC, have a deleterious germline or somatic mutation in BRCA1, BRCA2, ATM or another homologous recombination (HR) DNA repair gene that can serve as a molecular marke

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eae9b01b83a87a7b2feabb51b16f2237
https://doi.org/10.1200/jco.2018.36.6_suppl.tps388

Zobrazit plný text záznamu

Durable Remission in Recurrent T-Cell—Rich B-Cell Lymphoma with the Anti-CD20 Antibody Rituximab

Autor: Thomas S. Stanton, Roger A. Warnke, Yasodha Natkunam, Sandra J. Horning

Publikováno v: Clinical Lymphoma. 2:185-187

A diagnostic continuum exists between lymphocyte-predominant Hodgkin's disease, T-cell-rich B-cell lymphoma (TCRBCL), and diffuse large B-cell lymphoma. While TCRBCLs are uncommon, their clinical and morphologic presentation can mimic other Hodgkin's

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70b049068b855c9e904498eb8f58dbd8
https://doi.org/10.3816/clm.2001.n.025

Zobrazit plný text záznamu

Detection of the hemoglobin E mutation using the color complementation assay: application to complex genotyping

Autor: Farid F. Chehab, Patricia Cornett, Tina C. Warren, Stephen H. Embury, Thomas S. Stanton, Gerald L. Kropp

Publikováno v: Blood. 76:619-623

The color complementation assay (CCA) is a method of allele-specific DNA amplification by which competitive priming and extension of fluorescently labeled oligonucleotide primers determine the color of DNA amplification product. This diagnostic metho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5b385e89c984d728872177ae21ce5861
https://doi.org/10.1182/blood.v76.3.619.619

Zobrazit plný text záznamu

Chemotherapy of metastatic testicular cancer: Current status and future prospects

Autor: David R. Gandara, Edith A. Perez, Thomas S. Stanton

Publikováno v: World Journal of Urology. 8:20-26

Introduction of the chemotherapeutic agent cisplatin in 1974 initiated 15 years of progress in the management of metastatic testicular cancer at a pace virtually unprecedented in the history of medical oncology. With current cisplatin- and etoposide-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::77d4ad97382ca5ad4edf3f705a14cbc7
https://doi.org/10.1007/bf01576273

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání